Sleep disorders and their determinants in multiple system atrophy

I Ghorayeb, F Yekhlef, V Chrysostome, E Balestre, B Bioulac, F Tison

PATIENTS AND METHODS

The University of Bordeaux 2 ethical committee approved the study. Fifty seven consecutive patients with MSA underwent a standardised face to face interview and examination protocol to fulfill MSA clinical diagnostic criteria for “possible” and “probable” MSA. Comparison was made with 62 outpatients with PD, who were recruited in parallel and matched as a group for sex, age, and disease duration.

Sleep disorders are common in Parkinson’s disease (PD)1-3 and multiple system atrophy (MSA),4-6 with increasing evidence implicating the underlying pathological process.4-6 The latter is more diffuse in MSA and results in a more aggressive course and levodopa unresponsiveness.10 Although the two disorders share parkinsonism, little is known about whether sleep disorders during them are similar. A comparison of sleep disorders in the two conditions may prove useful in elucidating their determinants. Only one study has previously compared sleep disturbances in a small group of patients with PD or MSA.7 We therefore compared the incidence, characteristics, and determinants of sleep problems in a sample of 57 patients with MSA and 62 matched patients with PD.

OBJECTIVES: To evaluate the incidence, types, determinants, and consequences of sleep disorders in patients with multiple system atrophy (MSA) and determine whether their characteristics are similar to those of patients with Parkinson’s disease (PD).

METHODS: Information about sleep disorders was collected using a standardised questionnaire in an unselected group of 57 patients with MSA and in 62 patients with PD matched as a group for age, sex distribution, and disease duration.

RESULTS: Seventy percent of patients with MSA complained of sleep disorders compared with 51% of patients with PD (p=0.03). The most commonly reported sleep disorders were sleep fragmentation (52.5%), vocalisation (60%), REM sleep behaviour disorder (47.5%), and nocturnal stridor (19%). Except for sleep fragmentation, the incidence of these disorders was significantly higher than in PD. Sleep problems tended to be associated with more severe motor symptoms, longer disease duration, depression, and longer duration of levodopa treatment. Half of patients with MSA with sleep disorders complained of daytime somnolence compared with 30% of patients with PD. Daytime somnolence was significantly associated with disease severity in MSA.

CONCLUSION: This study shows that sleep disorders are more common in patients with MSA than in those with PD after the same duration of the disease, reflecting the more diffuse underlying pathological process in MSA.

RESULTS

The mean age (67.3 (SD 8.5) years), sex distribution, and mean disease duration (5.75 (SD 3.36) years) of the 57 patients with MSA did not differ significantly from those of the 62 patients with PD (65.2 (SD 8.7) years and 7 (SD 4.37) years respectively). Thirty percent of patients with MSA were classified as MSA-C and 70% as MSA-P.

Parkinsonism was significantly more severe in patients with MSA than in those with PD (mean Hoehn and Yahr score=3.23 (SD 1.36) v 2.18 (SD 0.76), p<0.0001; mean

Abbreviations: PD, Parkinson’s disease; MSA, multiple system atrophy; REM, rapid eye movement; RBD, REM sleep behaviour disorder; UPDRS, unified Parkinson’s disease rating scale; MMSE, mini mental state examination.
Sleep disorders in multiple system atrophy

Table 1  Nighttime problems in patients with Parkinson’s disease (PD) and multiple system atrophy (MSA)

<table>
<thead>
<tr>
<th>Patients (no)</th>
<th>SC</th>
<th>Insomnia</th>
<th>SF</th>
<th>EA</th>
<th>Vocalisation</th>
<th>RBD</th>
<th>RLS</th>
<th>Snoring</th>
<th>Stridor</th>
</tr>
</thead>
<tbody>
<tr>
<td>PD (62)</td>
<td>51</td>
<td>19</td>
<td>38.7</td>
<td>42</td>
<td>13</td>
<td>9.7</td>
<td>32</td>
<td>7.5*</td>
<td>12.5</td>
</tr>
<tr>
<td>MSA (57)</td>
<td>70*</td>
<td>20</td>
<td>52.5</td>
<td>32.5</td>
<td>60*</td>
<td>47.5*</td>
<td>12.5</td>
<td>72.5</td>
<td>19*</td>
</tr>
</tbody>
</table>

Values are percentages.
*p<0.05 when compared with patients with PD.
SC, Sleep complaints; SF, sleep fragmentation; EA, early awakening; RBD, rapid eye movement (REM) sleep behaviour disorder; RLS, restless legs syndrome.

Table 2  Clinical characteristics of patients with Parkinson’s disease (PD) or multiple system atrophy (MSA) with and without sleep complaints

<table>
<thead>
<tr>
<th></th>
<th>PD patients with sleep complaints</th>
<th>PD patients without sleep complaints</th>
<th>MSA patients with sleep complaints</th>
<th>MSA patients without sleep complaints</th>
</tr>
</thead>
<tbody>
<tr>
<td>Percentage</td>
<td>51</td>
<td>49</td>
<td>70*</td>
<td>30</td>
</tr>
<tr>
<td>Age (years)</td>
<td>66.2 (7.9)</td>
<td>64.2 (9.7)</td>
<td>67.5 (7.8)</td>
<td>67 (10.2)</td>
</tr>
<tr>
<td>Men (%)</td>
<td>58.06</td>
<td>60</td>
<td>62.5</td>
<td>23.3</td>
</tr>
<tr>
<td>Disease duration (years)</td>
<td>8 (4.5)</td>
<td>6 (4.1)</td>
<td>6.2 (3.2)</td>
<td>4.7 (3.6)</td>
</tr>
<tr>
<td>Hoehn and Yahr score</td>
<td>5.8 (4.0)</td>
<td>5.9 (4.0)</td>
<td>5.8 (4.0)</td>
<td>5.6 (4.0)</td>
</tr>
<tr>
<td>UPDRS-III score</td>
<td>31.2 (13.11)</td>
<td>29.8 (15.87)</td>
<td>54.3 (19.64)</td>
<td>42.9 (17.17)</td>
</tr>
<tr>
<td>Schwab and England score</td>
<td>70.2 (22.13)</td>
<td>75.6 (15.69)</td>
<td>50.1 (24.7)</td>
<td>44.1 (26.71)</td>
</tr>
<tr>
<td>MMSE score</td>
<td>27.6 (2.64)</td>
<td>27.7 (2.07)</td>
<td>25.7 (3.79)</td>
<td>26.5 (2.89)</td>
</tr>
<tr>
<td>Autonomic failure (%)</td>
<td>41.94</td>
<td>27.5</td>
<td>95</td>
<td>82.35</td>
</tr>
<tr>
<td>CES-D score</td>
<td>14.06 (10.37)</td>
<td>11.9 (10.59)</td>
<td>21.0 (11.39)</td>
<td>18.71 (9.1)</td>
</tr>
<tr>
<td>Antidepressant use (%)</td>
<td>35.48</td>
<td>17.24</td>
<td>42.5</td>
<td>52.94</td>
</tr>
<tr>
<td>Daily levodopa (mg)</td>
<td>626.61 (367.24)</td>
<td>521.5 (349.82)</td>
<td>565.63</td>
<td>484.56</td>
</tr>
<tr>
<td>Duration of levodopa therapy (years)</td>
<td>6.8 (4.01)**</td>
<td>3.99 (3.49)</td>
<td>4 (3.66)</td>
<td>2.71 (3.34)</td>
</tr>
<tr>
<td>Dopamine agonist use (%)</td>
<td>74.2**</td>
<td>37.8</td>
<td>32.5*</td>
<td>47.1</td>
</tr>
<tr>
<td>Amantadine use (%)</td>
<td>12.9</td>
<td>17.24</td>
<td>11.8</td>
<td>27.5</td>
</tr>
</tbody>
</table>

Values are presented as mean (SD) or percentages.
*p<0.05 when compared with PD patients with sleep complaints, **p<0.05 when compared with PD patients without sleep complaints.
PD, Unified Parkinson’s disease rating scale; MMSE, mini mental state examination; CES-D, Center for Epidemiological Studies depression scale.

UPDRS-III score=47.33 (SD 18.08) vs 29.65 (SD 12.85), p<0.0001; mean Schwab and England score=41.6 (SD 25.14) vs 73.06 (SD 19.13), p<0.0001. The mean daily levodopa dose was not significantly different in patients with MSA (752.7 (SD 362.1) mg) and those with PD (636.8 (SD 337) mg) nor was the mean duration of dopa treatment (4.4 (SD 3.82) years vs 5.8 (SD 3.97) years respectively). Some 37% of patients with MSA used dopamine agonists (bromocriptine, ropinirole, pergolide, piribedil, lisuride, apomorphine) v 57% of patients with PD (p=0.02), and 23% of patients with MSA used amantadine v 15% of patients with PD.

Incidence and types of sleep problems
Table 1 shows the percentage of patients reporting nighttime disturbances in each group. A significantly higher percentage of patients with MSA complained of sleep disorders compared with patients with PD (70% v 51%, p=0.03). A significantly higher percentage of patients with MSA reported nighttime vocalisation and RBD than patients with PD (60% v 13%, p<0.0001; 47.3% v 9.7%, p=0.0006 respectively). Nocturnal stridor was reported only by patients with MSA (19%, p=0.0004).

Determinants of sleep disturbances
Table 2 shows the clinical characteristics of patients with MSA or PD, with and without sleep complaints. Patients with MSA or PD with sleep complaints tended to have longer disease duration, higher mean motor scores (UPDRS-III and Hoehn and Yahr stage), were more disabled with respect to activities of daily life, and reported more depressive symptoms than those without sleep complaints. Both groups of patients with sleep complaints tended to use higher daily levodopa doses, and patients with PD more often used dopamine agonists than those without sleep complaints. Amantadine use was not associated with more common sleep problems in either group. Unlike in patients with PD, duration of dopa treatment in patients with MSA was not significantly associated with sleep disorders.

Consequences of sleep disturbances
Use of hypnotic or antidepressant drugs was not significantly different in patients with MSA or PD. Half of patients with MSA compared with 30% of patients with PD admitted daytime somnolence and were significantly more severely disabled than those without daytime somnolence (mean UPDRS-III score=55.8 (SD 15.6) v 42.7 (SD 19.4), p=0.03; mean Hoehn and Yahr stage=3.84 (SD 0.88) v 2.8 (SD 1.6), p=0.02).

DISCUSSION
This is the first questionnaire based study of nighttime problems in a large unselected MSA population compared with patients with PD matched for age, sex, and disease duration. Although such studies may be limited by the accuracy of self reporting compared with polysomnographic studies, they make it possible to screen a broader and more representative sample of patients.

Overall, patients with MSA reported significantly more nighttime problems than patients with PD. In agreement with previous studies, difficulty in getting to sleep was similar in the two groups, a finding previously suggested to be mostly related to age. As already noted in patients with PD, sleep fragmentation and early awakening were also often reported.
by patients with MSA. The higher incidence of sleep fragmentation in patients with MSA suggests that the disease severity may favour this. Indeed, as for patients with PD, the mean UPDRS-III and Hoehn and Yahr scores for sleep disordered patients with MSA were higher than in patients with MSA without sleep problems.

Nocturnal vocalisation and RBD were more common in MSA, the former possibly being an early manifestation of RBD in patients with MSA. This may reflect the more extensive brainstem pathology in MSA. Nocturnal stridor occurred in 19% of patients with MSA, a result in keeping with that obtained by polysomnographic studies. Snoring also tended to be more common in patients with MSA. None of our patients with PD reported stridor. This suggests that snoring and stridor are not confused by the patients' bed partners. Although of potential interest, body mass index and neck circumference were not assessed, and there was no obvious clinical evidence of a weight bias between the two groups.

The role of dopaminergic agents in sleep disruption remains a matter of debate. On the one hand, the efficacy of dopa treatment and dopamine agonists in our patients with PD may partly explain the reduced occurrence of sleep disturbances compared with patients with MSA, but on the other, dopaminergic drugs may disrupt sleep and induce daytime somnolence. Accordingly, duration of dopa treatment, but not daily dose, and agonist use were the most significantly associated with sleep disorders in patients with PD but not in those with MSA.

Even if higher depressive symptom scores were associated with sleep problems in both groups of patients, no significant association was found with antidepressant use. However, these variables may be dependent as both depression and antidepressants may cause sleep disorders.

More patients with MSA complained of daytime somnolence than patients with PD, arguing against the exclusive role of age, as proposed by others. Patients with MSA with daytime somnolence had significantly higher mean UPDRS-III and Hoehn and Yahr scores than those without, suggesting a probable role for degenerative process diffusion.

Conclusion

After the same duration of the disease, there was a higher incidence and variety of sleep disorders in patients with MSA than in those with PD. This paralleled the increasing severity of motor signs and the wider diffusion of the underlying degenerative process, which involves neuronal substrates for sleep organisation and maintenance, such as brainstem nuclei and/or basal ganglia.

ACKNOWLEDGEMENTS

This work was supported by a PHRC 1997 grant, Centre Hospitalier Universitaire de Bordeaux and CNRS (fellowship for I G).

Authors' affiliations

I Ghorayeb, B Bioulac, Service d’Explorations Fonctionnelles du Système Nerveux, Clinique du Sommeil, Hôpital Pellegrin, Place Amélie RaboLéon, 33076 Bordeaux cedex, France

F Yekhlef, V Chrysostome, F Tison, Service de Neurologie, Hôpital du Haut Lévêque, Avenue de Magellan, 33600 Pessac cedex, France

E Balestre, INSERM U330 Biostatistiques et Épidémiologie, Université Bordeaux 2, 146, rue Léo-Saignat, 33076 Bordeaux cedex, France

Correspondence to: Professor F Tison, Service de Neurologie, Hôpital du Haut Lévêque, Avenue de Magellan, 33600 Pessac cedex, France; francois.tison@chu-bordeaux.fr

Received 9 July 2001
In revised form 11 October 2001
Accepted 13 December 2001

REFERENCES


